Agency
Southeast Alaska Regional Health Consortium
Southeast Alaska Regional Health Consortium was paid $19.88M by Medicaid between Jan 2018 and Dec 2024, across 35 billing codes. Its largest line is H0020, Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) — 76% of everything it billed.
33Billing provider infoSOUTHEAST ALASKA REGIONAL HEALTH CONSORTIUM
JUNEAU, AK 99801
JUNEAU, AK 99801
33aNPI1194261594assigned 01/10/2017
33bProvider typeCommunity/Behavioral Health Agency
28Total paid$19.88M
24GClaims31,810
24DCodes billed35
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Community/Behavioral Health Agency providers in Alaska
Rank by total paid#6 of 87
Median peer was paid$2.46M
This provider vs. median8.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HARRIS, DANIEL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 575 | $207K | |
| 2019 | 1,364 | $432K | |
| 2020 | 1,163 | $464K | |
| 2021 | 1,188 | $444K | |
| 2022 | 19,778 | $12.92M | |
| 2023 | 6,091 | $4.35M | |
| 2024incomplete | 1,651 | $1.06M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | 76% | 20,789 | 1,124 | $15.15M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 11% | 3,054 | 2,532 | $2.12M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 6.7% | 2,216 | 1,584 | $1.34M |
| H2021 | Community-based wrap-around services, per 15 minutes | 2.7% | 709 | 329 | $528K |
| 80305 | <1% | 1,852 | 1,252 | $169K | |
| T1016 | Case management, each 15 minutes | <1% | 364 | 163 | $156K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 122 | 82 | $64K |
| T1007 | Alcohol and/or substance abuse services, treatment plan development and/or modification | <1% | 136 | 118 | $59K |
| 0011A | <1% | 61 | 61 | $45K | |
| 99442 | <1% | 118 | 60 | $44K | |
| 80306 | <1% | 77 | 39 | $37K | |
| 0012A | <1% | 49 | 47 | $34K |
23 more codes
| 80053 | Comprehensive metabolic panel | <1% | 56 | $25K |
| 0001A | <1% | 32 | $24K | |
| 0002A | <1% | 23 | $18K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 79 | $17K |
| H0002 | Behavioral health screening to determine eligibility for admission to treatment program | <1% | 138 | $17K |
| G0467 | Community health center visit, returning patient | <1% | 371 | $14K |
| H0001 | Alcohol and/or drug assessment | <1% | 26 | $11K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 281 | $9K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 13 | $3K |
| 91300 | 0% | 80 | $0.00 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 0% | 41 | $0.00 |
| 86708 | 0% | 56 | $0.00 | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 0% | 409 | $0.00 |
| 93268 | 0% | 91 | $0.00 | |
| 91301 | 0% | 112 | $0.00 | |
| 87522 | Neg quan hep c or qual rna | 0% | 53 | $0.00 |
| 86580 | 0% | 117 | $0.00 | |
| 86592 | 0% | 55 | $0.00 | |
| 36415 | Collection of venous blood by venipuncture | 0% | 87 | $0.00 |
| 87340 | 0% | 56 | $0.00 | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 0% | 20 | $0.00 |
| 86317 | 0% | 54 | $0.00 | |
| 90686 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHARRIS, DANIEL (CHIEF FINANCIAL OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.